| [1] |
Kurtz SM, Lau E, Watson H, et al. Economic burden of periprosthetic joint infection in the United States[J]. J Arthroplasty, 2012, 27(8 Suppl): 61－65.e1.
|
| [2] |
Dale H, Fenstad AM, Hallan G, et al. Increasing risk of prosthetic joint infection after total hip arthroplasty[J]. Acta Orthop, 2012, 83(5): 449－458.
|
| [3] |
边焱焱，程开源，常晓，等. 2011至2019年中国人工髋膝关节置换手术量的初步统计与分析[J]. 中华骨科杂志，2020, 40(21): 1453－1460.
|
| [4] |
Ferry T, Batailler C, Brosset S, et al. Medical innovations to maintain the function in patients with chronic PJI for whom explantation is not desirable: a pathophysiology-，multidisciplinary-，and experience-based approach[J/OL]. SICOT-J, 2020, 6: 26. DOI: 10.1051/sicotj/2020021.
|
| [5] |
Shoji MM, Chen AF. Biofilms in periprosthetic joint infections: areview of diagnostic modalities, current treatments, and future directions[J]. J Knee Surg, 2020, 33(2): 119－131.
|
| [6] |
Morris J, Kelly N, Elliott L, et al. Evaluation of bacteriophage anti-biofilm activity for potential control of orthopedic implant-related infections caused by Staphylococcus aureus[J]. Surg Infect, 2019, 20(1): 16－24.
|
| [7] |
Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases[J]. Nat Rev Microbiol, 2004, 2(2): 95－108.
|
| [8] |
Akanda ZZ, Taha M, Abdelbary H. Current review-The rise of bacteriophage as a unique therapeutic platform in treating peri-prosthetic joint infections[J]. J Orthop Res, 2018, 36(4): 1051－1060.
|
| [9] |
Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections[J]. Science, 1999, 284(5418): 1318－1322.
|
| [10] |
Høiby N, Bjarnsholt T, Givskov M, et al. Antibiotic resistance of bacterial biofilms[J]. Int J Antimicrob Agents, 2010, 35(4): 322－332.
|
| [11] |
Bjarnsholt T, Ciofu O, Molin S, et al. Applying insights from biofilm biology to drug development - can a new approach be developed？[J]. Nat Rev Drug Discov, 2013, 12(10): 791－808.
|
| [12] |
Steadman W, Chapman PR, Schuetz M, et al. Local antibiotic delivery options in prosthetic joint infection[J/OL]. Antibiotics, 2023, 12(4): 752. DOI: 10.3390/antibiotics12040752.
|
| [13] |
Kim L. Persister cells[J]. Annu Rev Microbiol, 2010, 64: 357－372.
|
| [14] |
van Belleghem JD, Manasherob R, Międzybrodzki R, et al. The rationale for using bacteriophage to treat and prevent periprosthetic joint infections[J/OL]. Front Microbiol, 2020, 11: 591021. DOI: 10.3389/fmicb.2020.591021.
|
| [15] |
Doub JB, Urish K, Chan B. Bacteriophage therapy for periprosthetic joint infections: current limitations and research needed to advance this therapeutic[J]. J Orthop Res, 2023, 41(5): 1097－1104.
|
| [16] |
Gbejuade HO, Lovering AM, Webb JC. The role of microbial biofilms in prosthetic joint infections[J]. Acta Orthop, 2015, 86(2): 147－158.
|
| [17] |
Totten KMC, Patel R. Phage activity against planktonic and biofilm Staphylococcus aureusperiprostheticjoint infection isolates[J/OL]. Antimicrob Agents Chemother, 2022, 66(1): e0187921. DOI: 10.1128/AAC.01879-21.
|
| [18] |
Botka T, Pantůček R, Mašlaňová I, et al. Lytic and genomic properties of spontaneous host-range Kayvirus mutants prove their suitability for upgrading phage therapeutics against staphylococci[J/OL]. Sci Rep, 2019, 9(1): 5475. DOI: 10.1038/s41598-019-41868-w.
|
| [19] |
van BelleghemJD, D&#x；browska K, Vaneechoutte M, et al. Interactions between bacteriophage, bacteria, and the mammalian immune system[J/OL]. Viruses, 2018, 11(1): 10. DOI: 10.3390/v11010010.
|
| [20] |
Sosa BR, Niu Y, Turajane K, et al. 2020 John Charnley Award: the antimicrobial potential of bacteriophage-derived lysin in a murine debridement, antibiotics, and implant retention model of prosthetic joint infection[J]. Bone Joint J, 2020, 102－B(7_Supple_B): 3－10.
|
| [21] |
程永帅，刘炜洁，于腾波，等. 噬菌体裂解酶对兔膝关节假体周围感染的影响[J]. 中华实验外科杂志，2018, 35(12): 2289－2291.
|
| [22] |
Gutiérrez D, Rodríguez-Rubio L, Martínez B, et al. Bacteriophages as weapons against bacterial biofilms in the food industry[J/OL]. Front Microbiol, 2016, 7: 825. DOI: 10.3389/fmicb.2016.00825.
|
| [23] |
Šuster K, Cör A. Induction of viable but non-culturable state in clinically relevant staphylococci and their detection with bacteriophage K[J/OL]. Antibiotics, 2023, 12(2): 311. DOI: 10.3390/antibiotics12020311.
|
| [24] |
Boyle KK, Wood S, Tarity TD. Low-virulence organisms and periprosthetic joint infection-biofilm considerations of these organisms[J]. Curr Rev Musculoskelet Med, 2018, 11(3): 409－419.
|
| [25] |
Šuster K, Cör A. Fast and specific detection of staphylococcal PJI with bacteriophage-based methods within 104 sonicate fluid samples[J]. J Orthop Res, 2022, 40(6): 1358－1364.
|
| [26] |
Šuster K, Podgornik A, Cör A. An alternative molecular approach for rapid and specific detection of clinically relevant bacteria causing prosthetic joint infections with bacteriophage K[J]. New Microbiol, 2020, 43(3): 107－114.
|
| [27] |
Gemmel F, van den Wyngaert H, Love C, et al. Prosthetic joint infections: radionuclide state-of-the-art imaging[J]. Eur J Nucl Med Mol Imaging, 2012, 39(5): 892－909.
|
| [28] |
Jacqueline C, Caillon J. Impact of bacterial biofilm on the treatment of prosthetic joint infections[J]. J Antimicrob Chemother, 2014，69(Suppl 1): i37－i40.
|
| [29] |
Bruttin A, Brüssow H. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy[J]. Antimicrob Agents Chemother, 2005, 49(7): 2874－2878.
|
| [30] |
Hadas H, Einav M, Fishov I, et al. Bacteriophage T4 development depends on the physiology of its host Escherichia coli[J]. Microbiology, 1997，143( Pt 1): 179－185.
|
| [31] |
Pearl S, Gabay C, Kishony R, et al. Nongenetic individuality in the host-phage interaction[J/OL]. PLoS Biol, 2008, 6(5): e120. DOI: 10.1371/journal.pbio.0060120.
|
| [32] |
Wright A, Hawkins CH, Anggård EE, et al. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy[J]. Clin Otolaryngol, 2009, 34(4): 349－357.
|
| [33] |
Ferry T, Leboucher G, Fevre C, et al. Salvage debridement, antibiotics and implant retention ( "DAIR" ) with local injection of a selected cocktail of bacteriophages: is it an option for an elderly patient with relapsing Staphylococcus aureusprosthetic-joint infection？[J/OL]. Open Forum Infect Dis, 2018, 5(11): ofy269. DOI: 10.1093/ofid/ofy269.
|
| [34] |
李朔，徐一宏，徐卫东. 人工关节置换术后感染的生物治疗方法及前景[J/CD]. 中华关节外科杂志(电子版), 2019, 13(2): 213－219.
|
| [35] |
van Belkum A, Gros MF, Ferry T, et al. Novel strategies to diagnose prosthetic or native bone and joint infections[J]. Expert Rev Anti Infect Ther, 2022, 20(3): 391－405.
|
| [36] |
DePalma BJ, Nandi S, Chaudhry W, et al. Assessment of staphylococcal clinical isolates from periprosthetic joint infections for potential bacteriophage therapy[J]. J Bone Joint Surg Am, 2022, 104(8): 693－699.
|
| [37] |
Donlan RM. Preventing biofilms of clinically relevant organisms using bacteriophage[J]. Trends Microbiol, 2009, 17(2): 66－72.
|
| [38] |
Łusiak-Szelachowska M, Zaczek M, Weber-Dąbrowska B, et al. Phage neutralization by sera of patients receiving phage therapy[J]. Viral Immunol, 2014, 27(6): 295－304.
|
| [39] |
Cano EJ, Caflisch KM, Bollyky PL, et al. Phage therapy for limb-threatening prosthetic knee Klebsiella pneumoniaeinfection: case report and in vitrocharacterization of anti-biofilm activity[J/OL]. Clin Infect Dis, 2021, 73(1): e144－e151. DOI: 10.1093/cid/ciaa705.
|
| [40] |
Insall JN, Thompson FM, Brause BD. Two-stage reimplantation for the salvage of infected total knee arthroplasty. 1983[J/OL]. J Bone Joint Surg Am, 2002, 84(3): 490. DOI: 10.2106/00004623-200203000-00024.
|
| [41] |
Fedorov E, Samokhin A, Kozlova Y, et al. Short-term outcomes of phage-antibiotic combination treatment in adult patients with periprosthetic hip joint infection[J/OL]. Viruses, 2023, 15(2): 499. DOI: 10.3390/v15020499.
|
| [42] |
Ferry T, Kolenda C, Batailler C, et al. Case report: arthroscopic "debridement antibiotics and implant retention" with local injection of personalized phage therapy to salvage a relapsing Pseudomonas aeruginosaprostheticknee infection[J/OL]. Front Med, 2021, 8: 569159. DOI: 10.3389/fmed.2021.569159.
|
| [43] |
Cesta N, Pini M, Mulas T, et al. Application of phage therapy in a case of a chronic hip-prosthetic joint infection due to Pseudomonas aeruginosa: an Italian real-life experience and in vitroanalysis[J/OL]. Open Forum Infect Dis, 2023, 10(2): ofad051. DOI: 10.1093/ofid/ofad051.
|
| [44] |
Ferry T, Kolenda C, Gustave CA, et al. Phage therapy in bone and joint infection: history, scientific basis, feasibility and perspectives in France[J]. Virologie, 2020, 24(1): 49－56.
|
| [45] |
Taha M, Abdelbary H, Ross FP, et al. Newinnovations in the treatment of PJI and biofilms-clinical and preclinical topics[J]. Curr Rev Musculoskelet Med, 2018, 11(3): 380－388.
|
| [46] |
Morris JL, Letson HL, Elliott L, et al. Evaluation of bacteriophage as an adjunct therapy for treatment of peri-prosthetic joint infection caused by Staphylococcus aureus[J/OL]. PLoS One, 2019, 14(12): e0226574. DOI: 10.1371/journal.pone.0226574.
|
| [47] |
Kaur S, Harjai K, Chhibber S. In vivoassessment of phage and linezolid basedimplant coatings for treatment of methicillin resistant S. aureus (MRSA) mediated orthopaedicdevice related infections[J/OL]. PLoS One, 2016, 11(6): e0157626. DOI: 10.1371/journal.pone.0157626.
|